Adaptimmune Therapeutics Net Worth
Adaptimmune Therapeutics Net Worth Breakdown | ADAP |
Adaptimmune Therapeutics Net Worth Analysis
Adaptimmune Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Adaptimmune Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Adaptimmune Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Adaptimmune Therapeutics' net worth analysis. One common approach is to calculate Adaptimmune Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Adaptimmune Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Adaptimmune Therapeutics' net worth. This approach calculates the present value of Adaptimmune Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Adaptimmune Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Adaptimmune Therapeutics' net worth. This involves comparing Adaptimmune Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Adaptimmune Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Adaptimmune Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adaptimmune Therapeutics' net worth research are outlined below:
| Adaptimmune Therapeutics generated a negative expected return over the last 90 days | |
| Adaptimmune Therapeutics has high historical volatility and very poor performance | |
| Adaptimmune Therapeutics may become a speculative penny stock | |
| The company reported the previous year's revenue of 60.51 M. Net Loss for the year was (114.31 M) with loss before overhead, payroll, taxes, and interest of (100.58 M). | |
| Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (141.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from insidermonkey.com: Adaptimmune Therapeutics plc Q1 2024 Earnings Call Transcript |
Adaptimmune Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adaptimmune Therapeutics Plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adaptimmune Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Adaptimmune Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adaptimmune Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptimmune Therapeutics Plc backward and forwards among themselves. Adaptimmune Therapeutics' institutional investor refers to the entity that pools money to purchase Adaptimmune Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 2 M | Fmr Inc | 2023-12-31 | 1.7 M | Tang Capital Management Llc | 2024-03-31 | 1.4 M | Syncona Portfolio Ltd. | 2023-12-31 | 1.4 M | Renaissance Technologies Corp | 2023-12-31 | 1.4 M | Jpmorgan Chase & Co | 2023-12-31 | 928.2 K | Millennium Management Llc | 2024-03-31 | 825.2 K | Redmile Group, Llc | 2024-03-31 | 715.6 K | Cubist Systematic Strategies, Llc | 2024-03-31 | 675.9 K | Matrix Capital Management Company, Llc | 2024-03-31 | 39 M | Ecor1 Capital, Llc | 2024-03-31 | 27.4 M |
Follow Adaptimmune Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 260.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adaptimmune Therapeutics's market, we take the total number of its shares issued and multiply it by Adaptimmune Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Adaptimmune Therapeutics' profitablity
Adaptimmune Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Adaptimmune Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Adaptimmune Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Adaptimmune Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Adaptimmune Therapeutics' profitability requires more research than a typical breakdown of Adaptimmune Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.43) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (2.89) | (2.75) |
When accessing Adaptimmune Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Adaptimmune Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adaptimmune Therapeutics' profitability and make more informed investment decisions.
The data published in Adaptimmune Therapeutics' official financial statements usually reflect Adaptimmune Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Adaptimmune Therapeutics. For example, before you start analyzing numbers published by Adaptimmune accountants, it's critical to develop an understanding of what Adaptimmune Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Adaptimmune Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adaptimmune Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Adaptimmune Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adaptimmune Therapeutics Plc. Please utilize our Beneish M Score to check the likelihood of Adaptimmune Therapeutics' management manipulating its earnings.
Evaluate Adaptimmune Therapeutics' management efficiency
Adaptimmune Therapeutics has return on total asset (ROA) of (0.2822) % which means that it has lost $0.2822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8761) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/31/2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 05/31/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.20 | 0.19 | |
| Net Current Asset Value | 228.6 M | 240.1 M | |
| Tangible Asset Value | 233.5 M | 245.2 M | |
| Tangible Book Value Per Share | 0.19 | 0.19 | |
| Enterprise Value Over EBITDA | (0.32) | (0.33) | |
| Price Book Value Ratio | 4.04 | 4.24 | |
| Enterprise Value Multiple | (0.32) | (0.33) | |
| Price Fair Value | 4.04 | 4.24 | |
| Enterprise Value | 40.7 M | 38.7 M |
The analysis of Adaptimmune Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Adaptimmune Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Adaptimmune Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 2.8989 | Revenue 60.3 M | Quarterly Revenue Growth (0.98) | Revenue Per Share 0.3 | Return On Equity (1.88) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptimmune Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptimmune Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptimmune Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tayton-martin Helen Katrina over a week ago Acquisition by Tayton-martin Helen Katrina of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 | ||
Wood Gavin over two weeks ago Acquisition by Wood Gavin of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 | ||
Ecor1 Capital, Llc over three weeks ago Discretionary transaction by Ecor1 Capital, Llc of tradable shares of Adaptimmune Therapeutics subject to Rule 16b-3 | ||
Piccina Cintia over two months ago Acquisition by Piccina Cintia of 1130832 shares of Adaptimmune Therapeutics at 0.0013 subject to Rule 16b-3 |
Adaptimmune Therapeutics Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Adaptimmune Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Adaptimmune Therapeutics Corporate Management
Elected by the shareholders, the Adaptimmune Therapeutics' board of directors comprises two types of representatives: Adaptimmune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptimmune. The board's role is to monitor Adaptimmune Therapeutics' management team and ensure that shareholders' interests are well served. Adaptimmune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptimmune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kerry Sharp | Senior Council | Profile | |
| Sbastien Desprez | VP Affairs | Profile | |
| Dana Lynch | Senior Communications | Profile | |
| Helen MBA | CoFounder Officer | Profile | |
| Bertrand Esq | Chief Officer | Profile | |
| Juli Miller | VP Relations | Profile |
How to buy Adaptimmune Stock?
The net worth of Adaptimmune Therapeutics Plc is the difference between its total assets and liabilities. Adaptimmune Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Adaptimmune Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Adaptimmune Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Adaptimmune Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Adaptimmune Therapeutics Plc stock.Already Invested in Adaptimmune Therapeutics Plc?
The danger of trading Adaptimmune Therapeutics Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptimmune Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptimmune Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptimmune Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adaptimmune Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptimmune Therapeutics Plc Stock. Highlighted below are key reports to facilitate an investment decision about Adaptimmune Therapeutics Plc Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Adaptimmune Stock analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share 0.3 | Quarterly Revenue Growth (0.98) | Return On Assets (0.28) | Return On Equity (1.88) |
The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.